
## **Years Ahead in HIV Prevention Research**

## **Time to Market**



	_
27 2028 Q3 Q4 Q1 Q2 Q3 Q4	
t efficacy imited initial supply dum of understanding reached on a (iara tly in development and could be rs in 2025 harket and platforms for vaginal rings	
fficacy limited initial supply 240/yr; 2024: ~\$180/yr; 2025: ~\$160/yr v licensed to 3 generics with likely n by 2027 n currently in development, with n expected early 2026 narket and platforms for injectables	
igh efficacy nd & PEPFAR commit to reaching 2 3 yrs clear nsed to 6 generics with likely on by 2027	
tion currently in development, with on expected in 2027 stand if market can bear 2 injectables	

July 2025